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Abstract
Heart transplantation (HTx) is a curative treatment for patients with advanced heart
failure (HF); however, since transplant opportunities are severely limited due to donor
shortage, the left ventricular assist device (LVAD) has become a standard therapy for
patients awaiting HTx. The role of echocardiography as a primary imaging modality to
monitor the allograft function in transplant recipients as well as to optimize LVAD
settings in LVAD recipients  has been expanding.  The purpose of  this  review is  to
highlight the clinical role of echocardiography in the management of patients under‐
going LVAD implantation and/or HTx. In particular, we overview (1) how to detect
LVAD malfunction and device‐associated complication in LVAD recipients  and (2)
echocardiographic assessments of cardiac allograft rejection in transplant recipients.
Keywords: heart failure, transplant, rejection, ventricular assist device, echocardiogra‐
phy
1. Introduction
Heart transplantation (HTx) provides considerable survival benefits for patients with end‐
stage heart failure, but it is available for only a small fraction of such patients all over the
world due to donor shortage [1]. Therefore, many heart transplant candidates require long‐
term support by a left ventricular assist device (LVAD) while they await transplantation [1,
2]. More recently, mechanical circulatory support has evolved into a standard therapy for
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patients with advanced heart failure, not only as a bridge to cardiac transplantation but also
as a destination therapy or a bridge to myocardial recovery [3].
Echocardiography is a primary imaging modality in the assessment of cardiac structure and
function in patients with advanced HF. In addition, echocardiography can be performed at the
patient’s bedside, and results are immediately available. In this review, we highlight the
effectiveness of echocardiography in the management of patients undergoing LVAD implan‐
tation and/or HTx.
2. Echocardiography in LVAD recipients
A growing number of heart transplant candidates require long‐term support by an LVAD while
they await cardiac transplantation. Further, LVAD therapy has become a standard therapy for
patients with advanced HF, not only as a bridge to cardiac transplantation but also as a
destination therapy or a bridge to myocardial recovery. Here, we focused on the usefulness of
echocardiography in patients undergoing LVAD implantation.
2.1. Preoperative assessment
It is important to assess the LVAD eligibility and rule out any contraindications against LVAD
surgery prior to an operation. Several structural issues that can be surgically corrected at the
time of LVAD implantation should be carefully evaluated prior to the LVAD surgery. The
presence of clots, especially at the apex, should be carefully assessed because it will increase
the risk of inflow cannula obstructions and/or perioperative stroke. Intracardiac shunts,
including patent foramen ovale, should also be carefully assessed before and during surgery.
Intracardiac shunts must be closed at the time of LVAD surgery. Further, coexisting valvular
heart disease should be assessed prior to the LVAD procedure. Concomitant valvular surgery
can be performed at the time of LVAD implantation; however, although such an additional
approach can provide possible benefits, data regarding its long‐term effect are limited, and
the indications are still controversial. Another important issue to be carefully evaluated
preoperatively includes right ventricular (RV) function because right ventricular failure (RVF)
after LVAD placement is associated with increased morbidity and mortality.
2.1.1. Preoperative valvular assessment
Regarding tricuspid regurgitation (TR), several previous papers have revealed that tricuspid
annular dilatation is highly associated with post‐LVAD right ventricular failure [4]. Kukucka
M et al. reviewed 122 patients without significant TR at the time of VAD implant and found
that a tricuspid annulus diameter >43 mm was an independent predictor of survival after
LVAD (Figure 1). On the other hand, whether the TR should be surgically managed at the time
of LVAD surgery is controversial. Dunlay et al. performed a literature search of randomized
controlled trials and observational studies (including 3249 patients) that compared the
outcome of concomitant tricuspid valve surgery at the time of LVAD with that of LVAD alone
[5]. They found that the addition of valvular surgery at the time of the LVAD procedure
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prolonged cardiopulmonary bypass times by an average of 31 minutes, but no differences were
found between the groups for acute renal failure, early mortality, or the need for a right
ventricular assist device. Having said that, a recent paper from Columbia University suggested
that concomitant tricuspid valve procedures at the time of LVAD surgery can be performed
safely and protect against worsening tricuspid regurgitation during the first two years of
support [6]. In either case, the severity of TR and annular size need to be assessed preopera‐
tively. Surgeons should also bear in mind that preexisting severe TR, especially with annular
size >43 mm, is at higher risk of adverse events after surgery.
Figure 1. The impact on tricuspid valve annulus dilation on post‐LVAD survival (quoted from Ref. [4]). Kaplan‐Meier
survival curves of patients with tricuspid valve (TV) annulus diameter <43 mm (blue) and >43 mm (red). Censored
patients are represented by vertical marks. Numbers of patients at risk at 0, 12, 24, and 36 months of follow‐up are
presented above the x‐axis (log‐rank test, p = 0.007).
Aortic insufficiency (AI) occurs in up to 50% of patients within 1 year after continuous flow
LVAD implantation. Although de novo AI can be commonly seen postoperatively, the presence
of more than mild AI as well as any structural abnormality, as detected by transthoracic
echocardiography (TTE), should be reported to the LVAD surgery team. In cases with poor
TTE images, the results derived from intraoperative transesophageal echocardiography (TEE)
should be carefully discussed. The valvular morphology, valvular calcification, possible fusion,
and myxomatous changes should also be reported to the surgeons. The recently published
comprehensive review of AI post‐LVAD by Cowger et al. suggested the importance of
intraoperative TEE to detect unmasked AI [7]. During the initiation of continuous flow LVAD
support, as LV filling pressures drop with early unloading, the gradient between the aortic
root and the LV increases, potentially exposing significant AI that was previously unrecog‐
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nized. Because AI severity can be associated with an increase in pump speeds, we can
quantitatively assess AI severity at different pump speeds to consider the necessity of con‐
comitant aortic valve surgery in an operating room. This review summarized the risk and
benefits of aortic valve surgery at the time of LVAD (Table 1).
Strategy Pros Cons
Partial closure with
a single central stitch
(Park’s stitch)
• Simple and effective when the
leaflet tissue has adequate tensile
strength to hold sutures
• Permit blood ejection through
the aortic valve
• Questionable durability
• Risk of progression to aortic stenosis
• Need for AVR in the event of
myocardial recovery leading to
LVAD explant
Modified Park’s stitch—
additional pledgeted
mattress suture
between the central stitch
and each commissure
• Relatively simple and can
be effective, even if leaflets are thin
• Permits blood ejection through
the aortic valve but could be
reduced compared to single
central stitch
• Questionable durability
• Risk of progression to aortic stenosis
• Need for AVR in the event of
myocardial recovery leading to
LVAD explant
Complete closure of the
ventriculo‐aortic juncture
with a circular patch
• Simple with relatively
fast repair time
• Long‐term durability
• No blood ejection through the
aortic valve
• Risk of thrombus formation
• Risk of death in the case of pump
stoppage or failure
Replacement of
incompetent aortic valve
with bioprosthetic
valve
• Maintenance of valve opening
in the postoperative period
• Testing for cardiac recovery
• Tolerance to exercise
• Increase CPB and cross‐clamp time
• Risk of leaflet fusion
• Risk of valvular and subvalvular
thrombus formation due to fresh
suture lines combined with decreased
flow across the new valve
Table 1. Pros and cons of surgical management strategies of the native aortic valve (quoted from Ref. [7]).
Mitral valve insufficiency has fewer effects on postoperative outcome compared with aortic
and tricuspid valve insufficiency. Indeed, a significant number of patients who had severe
mitral regurgitation due to annulus dilatation and tethered pupillary muscle preoperatively
showed a remarkable decrease in mitral regurgitation flow under LVAD support [8]. Although
mitral valve surgery at the time of LVAD implant to correct severe mitral regurgitation does
not affect postoperative mortality or cause other adverse events, the procedure can be consid‐
ered in cases undergoing an LVAD procedure as a bridge to recovery. In addition, concomitant
mitral valve repair can decrease pulmonary vascular resistance [9]. Kitada et al. investigated
preoperative echocardiographic features associated with persistent mitral regurgitation after
LVAD implantation (Figure 2) [10]. They found that the posterior displacement of the coapta‐
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tion point of a mitral leaflet (30 vs. 24 mm), papillary muscle distance (49 vs. 43 mm), and
tethering area (353 vs. 299 mm2) before surgery were greater in patients who had persistent
moderate to severe mitral regurgitation post‐LVAD than those in patients who did not have
significant MR postoperatively. A multivariate analysis showed that the posterior displace‐
ment was the only independent predictor for persistent MR.
Figure 2. The measurements of echocardiographic parameters to quantify the mitral leaflet configurations in 2D echo‐
cardiography (quoted from Ref. [10]). DA, apical displacement; DP, posterior displacement; LVEDD, left ventricular
end diastolic dimension.
2.1.2. Preoperative and perioperative right ventricular assessment
Right ventricular failure (RVF) remains a major cause of morbidity and mortality following
LVAD surgery. The incidence of RVF post‐LVAD is 10–30% despite the recent improvements
in device technology and postoperative patient management. Under LVAD support, right
ventricular (RV) preload increases as a result of increased circulatory volume, whereas RV
afterload is expected to decrease, secondary to improvement in pulmonary vascular resist‐
ance [11]. A sepal wall shift induced by LVAD alters the RV structure, which may worsen RV
contractile and relaxation abnormalities. Therefore, when considering RV systolic and diastolic
reserve before and also after surgery, it is important to identify which patients may need RV‐
specific mechanical and medical support post‐LVAD [12].
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Study Patients RVF definition
and rate
Multivariable predictors Echocardiographic RV
parameters considered
Michigan RV
failure risk
score (2008)a
197 LVADs
28 CF‐LVAD
94% BTT
Need for RVAD/
inotropes RVF
rate: 35%
Preoperative vasopressors (4 pts)
AST ≥80 IU/L (2 pts)
Bilirubin ≥2.0 mg/dL (2.5 pts)
Creatinine ≥2.3 mg/dL (3 pts)
RV systolic function
(visual
semiquantitative)
TR (visual
semiquantitative)
Penn RVAD
risk scoreb
(2008)
266 LVADs
6 CF‐LVAD
BTT vs. DT not
reported
Need for RVAD
RVF rate: 37%
Cardiac index ≤2.2 L/min/m2
RVSWI ≤0.25 mm Hg × L/m2
Severe RV dysfunction
Creatinine ≥1.9 mg/dL
Prior cardiac surgery
Systolic BP ≤96 mm Hg
RV systolic function
(visual
semiquantitative)
Utah RV risk
scorec (2010)
175 LVADs
25 CF‐LVAD
58% BTT, 42% DT
Need for RVAD/
inotropes/
inhaled NO
RVF rate: 44%
DT indication (3.5 pts)
IABP (4 pts)
PVR (1–4 pts)
Inotrope dependency (2.5 pts)
Obesity (2 pts)
ACEI or ARB use (−2.5 pts)
β‐blocker use (2 pts)
Right atrial area
Kormosd (2010)484 LVADs
All CF‐LVAD
BTT 100%
Need for RVAD/
inotropes
RVF rate: 20.2%
CVP/PCWP >0.63 (OR, 2.3)
Need for preoperative ventilator
support (OR, 5.5)BUN >39 mg/dL
(OR, 2.1)
None
Pittsburgh
Decision Treee
(2012)
183 LVADs
40 CF‐LVAD
BTT vs. DT not
reported
Need for RVAD
RVF rate: 15%
Age, heart rate, transpulmonary
gradient; right atrial pressure; INR,
white blood cell count, ALT, number
of inotropic agents
None
CRITTf (2013) 167 LVADs, all
CF‐LVAD
51 BiVADsBTT vs.
DT not reported
Need for BiVAD
RVF rate: 23%
CVP >15 mm Hg (C)
Severe RV dysfunction (R)
Preoperative intubation (I)
Severe TR (T)
Heart rate >100 (tachycardia [T])
RV systolic function
(visual
semiquantitative)
Severe TR (visual
semiquantitative)
ACEI, angiotensin‐converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker;
AST, aspartate aminotransferase; BiVAD, biventricular assist device; BP, blood pressure; BTT, bridge to transplantation;
BUN, blood urea nitrogen; CF, continuous flow; CRITT, central venous pressure‐RV dysfunction‐preoperative
intubation‐severe tricuspid regurgitation‐tachycardia; CVP, central venous pressure; DT, destination therapy; IABP;
intra‐aortic balloon pump; INR, international normalized ratio; ITT, intention to treat; LVAD, left ventricular assist
device; NO, nitric oxide; OR, odds ratio; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular
resistance; RV, right ventricle; RVAD, right ventricular assist device; RVF, right ventricular failure; RVSWI, right
ventricular stroke work index; and TR, tricuspid regurgitation.
The data were obtained from the following papers: (a) Matthews JC, et al. J Am Coll Cardiol. 2008;51:2163–2172; (b)
Fitzpatrick JR III, et al. J Heart Lung Transplant. 2008;27:1286–1292; (c) Drakos SG, et al. Am J Cardiol. 2010;105:1030–
1035; (d) Kormos RL, et al; HeartMate II Clinical Investigators. J Thorac Cardiovasc Surg. 2010;139:1316–1324; (e) Wang
Y, et al. J Heart Lung Transplant. 2012;31:140–149; (f) Atluri P, et al. Ann Thorac Surg. 2013;96:857–863.
Table 2. Clinical risk prediction scores for right ventricular failure in left ventricular assist device recipients (quoted
from Ref. [13]).
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Table 2 summarizes the clinical risk prediction scores that have been cited in the recently
published review literature [13]. In addition to these risk scores, serial echocardiographic
assessments are helpful in evaluating RV functional reserve prior to surgery. Previously
reported echocardiographic parameters associated with the risk for developing RVF after
LVAD implantation have included tricuspid annular dilation (>43 mm) [4], tricuspid annular
motion (8 vs. 15 mm) [14], and RV‐to‐LV end‐diastolic diameter ratio (>0.72) [15]. However, it
is sometimes technically difficult to obtain ideal RV images that allow quantitative assessments
of patients with advanced heart failure, particularly if the patients are severely congested,
intubated, and/or have a markedly enlarged left ventricle (LV) that obscures the right ventricle
(RV) [16]. Kato et al. focused only on left‐sided 2D echo parameters that can predict RVF post‐
LVAD. They showed that patients with relatively small LV size, preserved LV contraction, and
a dilated left atrium were at higher risk for RVF after LVAD surgery (Figure 3) [16]. In addition
to the conventional echo parameters, Grant et al. reported that the incremental role of RV strain
to predict RVF [17]. More recently, Kato et al. reported that serial echocardiograms using tissue
Doppler imaging (TDI) and speckle tracking echocardiography (STE) before and soon after
(within 72 hours) LVAD surgery may aid in identifying the need to initiate targeted RVF‐
specific therapy [12]. In this study, RV stiffness (as reflected by TDI‐derived E/E′) and decreased
RV contractility (as reflected by TDI‐derived S′ and RV longitudinal strain) before and soon
after LVAD surgery were found to be useful parameters to include in the perioperative
management of LVAD patients (Figure 4).
Figure 3. Left ventricular echocardiographic right ventricular failure score (LV‐for‐Echo‐RVF) based on two‐dimension‐
al echocardiographic left‐sided heart parameters (quoted from Ref. [16]). (A) Points associated with value of each vari‐
able. (B) Sensitivity and specificity of sum of points associated with right ventricular failure development after left
ventricular assist device placement. (C) Representative 2D echo images in patients developing RVF post‐LVAD. (D) Re‐
ceiver operating characteristics curve for LV echocardiographic RVF score. AUC, area under the curve.
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Figure 4. Representative global RV longitudinal strain and TDI obtained before surgery from a patient without RVF
after LVAD and from a patient with RVF after LVAD (quoted from Ref. [18]). (A) The right ventricular (RV) global lon‐
gitudinal strain; tissue Doppler image (TDI)‐derived S′ and E′ for patient A was −14.3%, 7.8 cm/s and −10.8 cm/s, re‐
spectively. (B) These parameters were −6.2%, 4.6 cm/s and −5.3 cm/s, respectively. LVAD, left ventricular assist device;
RVF, right ventricular failure.
2.2. Perioperative assessment
Other than the speed adjustment to avoid RV failure due to excessive RV preload by LVAD
support, several important points should be evaluated by intraoperative TEE. First, de‐airing
of the heart chamber should be confirmed. Careful observation of trapped air at the site of
anastomosis sites and around the LVAD inflow/outflow cannula is required [18]. Second,
adjusting LV speed to maintain appropriate LV unloading without a septal shift under TEE
guidance is required. The positioning of the inflow cannula at the apex should be monitored
by TEE as well. Third, as mentioned above, the existence of valvular diseases and intracardiac
shunts, which can be corrected simultaneously at the time of LVAD implantation, should be
communicated to the surgeons. Finally, pericardial effusion and its amount should also be
carefully observed by TEE. Cardiac tamponade can occur relatively often because patients
under LVAD support require sufficient anticoagulation soon after surgery to prevent clot
formation at the cannula and inside the device.
2.3. Postoperative assessment
Table 3 illustrates the checklist that will help sonographers/echocardiologists to perform an
LVAD echo. In general, we can simply summarize the purposes of echo in LVAD recipients as
follows: (1) to carefully monitor device malfunction, (2) to adjust appropriate LVAD setting/
speed (appropriate peripheral perfusion and RV preload), and (3) to evaluate myocardial
recovery and to seek optimal timing for LVAD weaning.
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The points to be evaluated by TEE on a periodic basis are as follows: the location and thrombus
at the inflow cannula; LV cavity diameters; septal position; RV function; valvular regurgitation,
especially about the aortic valve opening/intervals and regurgitation.
View Points to be checked
Parasternal
views 
• LV dimensions (ensure they are taken on axis)
• AV opening (long acquisitions, use long and short axis, and M‐mode)
• Mitral regurgitation (tethering is the hallmark of functional regurgitation, and the degree may
change according to LVAD rpm)
• Consider evaluating cardiac output through RV out flow
Apical views • Evaluate LV and RV function
• Evaluate inlet cannula flow (position and suctioning)
• Rule out thrombus in LV, RV, LA, and RA (use contrast as needed)
• Evaluate aortic regurgitation
Image the inlet
cannula
• Use multiple views including nonstandard
• Rule out thrombus or other cause of obstruction (use contrast as needed)
• Positioning (against LV wall)
Table 3. Echo LVAD checklist.
2.3.1. General postoperative assessment in LVAD recipients
Recommendations for device speed adjustment include the target measures of mean arterial
pressure above 65 mmHg, maintaining the position of interventricular septum and shape, and
intermittent aortic valve opening, under the condition of no more than mild mitral regurgita‐
tion to ensure appropriate unloading of the LV. Optimization of speed settings is extremely
important to prevent several of the key complications associated with chronic LVAD support.
The importance of ensuring the middle septal position for optimal RV function has been well
established [19, 20].
Serially monitoring the timing and its interval of aortic valve opening in all LVAD recipients
are necessary. Also, adjusting the LVAD speed to maintain the aortic valve opening is important
to prevent the development of aortic valve regurgitation. At least 10 cardiac cycles should be
recorded to evaluate the aortic valve opening. Because the interval of aortic valve opening, LV
diameter, and grade of MR entirely depend on the degree of LV unloading, the LVAD setting
together with the echo report needs to be recorded (Figure 5). Aortic regurgitation is sometimes
seen with atypical timing (Figure 6) or continuously, both during the diastolic and systolic
phases [21].
Cardiac output using RV outflow‐derived Doppler estimation can be calculated as follows:
cardiac output = stroke volume × heart rate, stroke volume = π × (RV outflow diameter/2)2 ×
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time velocity integral at RV outflow. In patients who have at least an intermittent aortic valve
opening, RV cardiac output minus LV outflow‐derived cardiac output is equivalent to the
estimated pump flow.
Figure 5. Representative images in a LVAD recipient with different LVAD speeds. This patient received HeartMate II
(Thoratec Corp) implantation. Under 8400 rpm, the aortic valve opened intermittently, and the ejection time was only
75 ms. When we set the speed down to 8200, the aortic valve opened every beat, but due to less unloading, the LV
diameter increased and the amount of mitral regurgitation also increased.
Figure 6. Aortic regurgitation during systolic phase accompanied by mitral regurgitation in patients with a continu‐
ous‐flow left ventricular assist device (quoted from Ref. [22]). Echo images obtained from a patient undergoing LVAD
implantation who showed systolic‐phase aortic regurgitation (AR). The timing of the regurgitation jet started at the
mid‐systolic phase and ended at the early diastolic phase (A). The AR occurred slightly after the onset of mitral regur‐
gitation (MR) (B), and both MR and AR timings were consistent with the systolic phase. No remarkable AR jet was
documented during the diastolic phase. The AV was mostly closed throughout the cycles, which opens once every 8–10
beats (C). The mean pressure gradients of the trans‐AV and trans‐mitral valve based on the continuous wave Doppler
measurements of AR (D) and MR flow (E) were 3.7 and 24.3 mmHg, respectively. The morphology of AV annulus
changes through the cycles irrespective of the AV opening, with the AV annulus abnormally distorted and dilated dur‐
ing early mid‐systole (F), whereas the septum wall as well as the AV annulus edge slightly pushed toward the LV dur‐
ing diastole (G).
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Serial assessments of pulmonary artery pressure by Doppler‐derived TR pressure gradients
are also important. In general, LVAD support can successfully unload LV, which results in the
correction of pulmonary hypertension due to left‐sided heart failure. However, some patients
have showed residual pulmonary vascular resistance post‐LVAD; therefore, echo‐guided
optimal medical therapy, including the necessity of pulmonary dilators such as PDE5 inhibitors
(sildenafil®, etc.), is required.
2.3.2. Detection of LVAD malfunction
The careful observation of the inflow cannula is critically important. By using multiple views,
including nonstandard ones, the thrombus or other causes of obstruction should be ruled out.
The direction of the inflow cannula should also be reported. The direction may sometimes
change after the surgery and direct toward the lateral wall, which may cause suctioning or
inadequate LVAD support. Contrast echocardiography can provide additional information.
Detecting the outflow cannula obstruction by echocardiography is difficult, but practitioners
should try to find a good echo window and investigate any abnormality, including kinking
(Figure 7) [22, 23].
Figure 7. Cases of LVAD malfunction detected by echocardiography (quoted from Refs. [23, 24]). Left: A 29‐year‐old
male developed low output syndrome 5 months after LVAD implantation. Echocardiography revealed pendulating ob‐
stacles at the inflow cannula of the LVAD. The obstacle was removed surgically, which histologically turned out to be
myocardium with fibrous tissue and thrombi. Right: A 53‐year‐old man undergoing LVAD implantation developed
low output syndrome. Echocardiography indicated distortion of the outflow cannula of the LVAD. A 3D CT also
showed the kinking of the cannula. The autopsy revealed thrombus at the kinking site.
The protocol for a ramp study was established by Uriel N [20]. It is useful in optimizing LVAD
settings and in diagnosing device malfunctions. Ramp test echocardiography can be per‐
formed at the time of discharge for speed optimization and/or if device malfunction is
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suspected (Figure 8) [24]. The patient’s left ventricular size, the frequency of the aortic valve
opening, valvular insufficiency, blood pressure, and continuous flow‐LVAD parameters
should be recorded according to the increments of the device speed. Serial assessments of ramp
tests are also helpful to detect LVAD clots [24].
Figure 8. A representative case with device thrombosis was detected by a ramp echocardiography device (quoted from
Ref. [24]). A case of a 29‐year‐old woman undergoing HeartMate II LVAD implantation; serial ramp studies were used
to diagnose intradevice thrombus after device implantation. The first ramp study on postoperative day (POD) 26 re‐
vealed an adequate reduction in ventricular size according to the increase in LVAD. The patient was discharged home
and received routine anticoagulation maintenance therapy. However, a second ramp test was performed on POD 56
due to increased lactase dehydrogenase and brain natriuretic peptide levels and showed a marked increase in the LV
chamber size without an adequate response to the LVAD speed changes. Given the suspicion for partial pump throm‐
bosis, the patient was immediately hospitalized and received intravenous heparin infusion. The patient eventually un‐
derwent cardiac transplant successfully, and the partial clot was found inside of the pump (lower panel).
2.3.3. Assessment of native cardiac function
It is important to assess native LV function, especially in patients receiving LVAD as a bridge
to recovery. We cannot assess LV function without turning off the LVAD because it drastically
affects preload and afterload; therefore, we need to reduce the LVAD speed under adequate
anticoagulation during weaning test echocardiography. Strain assessment has been reported
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to be more sensitive in evaluating the myocardial systolic and diastolic reserve, and 2D speckle
tracing echocardiography for the assessment of myocardial recovery in LVAD recipients may
be useful [25].
3. Echocardiography in transplant recipients
3.1. Donor heart evaluation
Evaluating a donor heart as accurately as possible at the time of procurement provides essential
information to a recipient team leading the delicate posttransplant management of the heart
[26]. If an organ procurement team has a cardiologist or sonographer who knows which patient
is going to receive the heart, the team can gather detailed information by bedside echocar‐
diography on the donor in light of the potential recipient’s conditions at the organ procure‐
ment.
Measuring the heart size of the donor from bedside echocardiography at the time of organ
procurement can provide useful information for judging the appropriateness of proceeding
with the heart transplant in the case of a donor‐recipient size mismatch. The wall thickness of
the donor heart may also be useful information for optimizing the medical therapy after
transplantation, as well as for deciding whether or not to use the organ. Information regarding
the presence or absence of a septal defect would be of help to surgeons planning the additional
procedure of septal closure at the time of transplantation. Information about the coronary flow
in the left anterior descending artery of the donor heart, especially in cases with coronary risk
factors, is useful for judging the availability of the heart, as well as for considering issues related
to posttransplant medical management. Finally, information about preexisting localized wall
motion abnormalities from bedside echocardiography is useful for speculating on the possi‐
bility of rejection or other reasons for wall motion abnormality after transplant surgery.
According to such information, the team can make a final decision whether or not to harvest
the heart. For example, the donor heart may be relatively small for the potential recipient. If a
donor heart with a lower limit of normal systolic function shows decreased coronary flow and
localized right heart wall motion abnormality, the heart should be declined in cases where the
potential recipients have moderately high pulmonary vascular resistance. Such recipients need
to receive a donor heart with good right ventricular function.
3.2. A noninvasive rejection diagnosis
Advances in immunosuppressive therapy have resulted in a marked decrease in the incidence
of acute allograft rejection in heart transplant recipients; however, acute rejection still remains
an important determinant factor for long‐term morbidity and mortality. Acute rejection can
result in not only the immediate risk of graft loss or heart failure but also of subsequent allograft
vasculopathy [27]. Therefore, early diagnosis of rejection and consequent timely treatment are
crucial for the early and long‐term care in heart transplant recipients. Detection of allograft
rejection based on the findings derived from endomyocardial biopsy (EMB) is still a gold
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standard; however, EMB is invasive, cost and time consuming, and may have a possibility of
sampling error and interobserver variability. Although many noninvasive modalities, includ‐
ing radionuclide imaging, MRI, and gene expression profiling, have been investigated for their
potential to detect rejection, none of them have been found to be sufficient for replacing EMB.
Echocardiography has been routinely used in the management of cardiac transplant recipients.
Indeed, it is an easily applicable, repeatable, and powerful noninvasive tool in the management
of posttransplant recipients [28].
Variables Characteristics and pitfalls
LVEF ↓
LV %FS ↓
• Occurs in the late phase of the rejection process
• Mild/moderate rejection cannot be detected
LV wall thickness ↑
LV mass ↑
• May be related to inflammatory cell infiltration
• Myocardial edema/preoperative ischemia also cause increase in LV wall thickness; so difficult
to interpret during early postoperative periods
Mitral E/A ratio ↑
Mitral DcT ↓
IVRT ↓
• Abnormal filling pattern/restrictive physiology is associated with rejection
• Relatively pre/after‐load dependent
• Doppler angle dependent
• Heart rate dependent (not appropriate for patients with tachycardia)
TEI Index* (MPI) ↑  • Can evaluate global ventricular performance (both systolic and diastolic)
• Derived from Doppler‐derived time intervals
• HR independent
Pericardial effusion↑ • May be related to the inflammatory process of rejection, but can have many causes, especially
during the early postoperative phase
A, late diastolic mitral inflow velocity; DcT, deceleration time; E, early diastolic mitral inflow velocity; EF, ejection
fraction; FS, fractional shortening; LV, left ventricle, left ventricular; IVRT, isovolumic relaxation time; IMP, myocardial
performance index. *MPI = (isovolumic contraction time – IVRT)/ejection time.
Table 4. Conventional echocardiographic variables associated with rejections (quoted from Ref. [29]).
3.2.1. Conventional echocardiography
Table 4 summarizes the conventional echocardiographic parameters associated with acute
cellular rejection [28]. Conventional echocardiography soon after the surgery can provide
information about global systolic and diastolic functions, wall motion abnormality, and the
hemodynamics of the transplanted hearts. Any apparent abnormal findings such as remark‐
able systolic and/or diastolic impairment may acute or hyperacute rejection, including
antibody‐mediated rejection, although primary graft failure, donor‐related graft dysfunction,
and any perioperative accidents should also be considered. The ability of conventional echo
parameters to detect rejection is still limited to severe clinically detectable rejection. However,
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the findings are still useful for assessing responsiveness to treatment. In general, patients with
rejection develop restrictive physiology accompanied by various degrees of systolic dysfunc‐
tion. Valantine HA et al. reported that a 15% decrease in mitral deceleration time or isovolumic
relaxation time (IVRT) is associated with biopsy proven rejection [29]. More recently, Sun et
al. reported that a combination of IVRT less than 90 ms, a mitral E/A ratio more than 1.7, and
other clinical parameters is independently associated with rejection [30]. However, because
transplant recipients usually have higher resting heart rates than the nontransplant population
due to denervation, their mitral E and A waves can be fused. Indeed, it is difficult to obtain
clear Doppler waves from transplant recipients. They frequently have extended adhesion of
the transplanted heart to the chest cavity, which hinders the acquisition of an appropriate
Doppler angle. The TEI index or myocardial performance index (MPI), which is a parameter
of a Doppler‐derived combination of systolic and diastolic time intervals, is a useful parameter
in patients with E‐A fusion and high heart rate; therefore, the MPI has the potential to detect
rejection more accurately than traditional Doppler indices [31]. Representative conventional
2D echo images associated with and without rejection are shown in Figure 9.
Figure 9. Representative 2D echocardiography in a patient with and without cellular rejection. Representative conven‐
tional 2D echocardiograms obtained from a 26‐year‐old female transplant recipient at the time when her EMB showed
conventional ISHLT grade 0 (left) and ISHLT grade 3a rejection (right). The posterior wall thickness of LV and the LV
mass index without rejection (left) were 9 mm and 88 g/m2, respectively. The same parameters associated with rejection
(right) were 13 mm and 112 g/m2. The arrow in the right lower panel indicates a pericardial effusion. EMB, endomyo‐
cardial biopsies; ISHLT, International Society for Heart and Lung Transplantation; LV, left ventricular and left ventricle.
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Variables Characteristics and pitfalls
TDI derived E′ ↓ A′ ↓
E/E′ ↑
• Reflecting increased LV filling pressure/relaxation abnormalities
• Angle dependent
TDI‐derived longitudinal systolic
strain ↓
TDI‐derived radial systolic strain ↓
• Reflecting both systolic and diastolic abnormalities
• Possibility of reflecting heterogeneous myocardial abnormalities
• Ability to detect subclinical rejection
• Angle dependent
• Frame rate limitations
TDI‐derived diastolic strain rate ↓ • Reflecting relaxation abnormalities
• Ability to detect subclinical rejection
• Angle dependent
• Frame rate limitations
2D‐STE‐derived LV torsion ↓ • Reflecting relaxation abnormalities
• Ability to detect subclinical rejection
• Angle independent
• Values can be calculated offline using stored 2D images
2D‐STE‐derived global radial
systolic strain ↓
• Reflecting both systolic and diastolic abnormalities
• Possibility of reflecting heterogeneous myocardial abnormalities
• Ability to detect subclinical rejection
• Angle independent
• Values can be calculated offline using stored 2D images
2D‐STE‐derived systolic and
diastolic global strain rate ↓
• May be more sensitive for the early detection of rejection than systolic and early
diastolic global strains
• Angle independent
• Values can be calculated offline using stored 2D images
A′, late diastolic mitral annular velocity, E′, early diastolic mitral annular tissue velocity. * LV torsion = (apical end‐
systolic rotation) – (basal end‐systolic rotation).
Table 5. Tissue‐Doppler imaging and 2D‐speckle‐tracking echocardiography‐derived variables associated with
rejections (quoted from Ref. [29]).
3.2.2. Tissue Doppler imaging and speckle tracking echocardiography
Tissue Doppler imaging (TDI) enables the measurements of systolic and diastolic velocities
within the myocardium. Several studies have evaluated the usefulness of TDI‐derived mitral
annular velocities to detect allograft rejection, which are summarized in Table 5 [28]. Strain
rate analysis has a potential to detect even mild rejection. Kato TS et al. reported that the
attenuation of LV longitudinal strain and the diastolic strain rate derived from TDI were
associated with conventional ISHLT (International Society for Heart and Lung Transplanta‐
tion) grade 1b or higher rejection without hemodynamic alterations (Figure 10) [32]. Marciniak
et al. found significantly lower LV longitudinal and radial peak systolic strain and strain rate
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values in patients with conventional ISHLT grade 1b or higher rejection. TDI‐derived strain
and strain rate potentially reflect abnormalities [33].
Figure 10. Representative TDI‐derived strain analysis in a patient with and without rejection (quoted from Ref. [33]).
Representative pathological findings for EMB specimens (a, b) and strain analysis (c, d) of HTx with ISHLT grade 0 (a,
c) or 3a (b, d) rejection. Sections in (a) and (b) were stained with hematoxylin‐eosin; scale bars, 100 mm. EMB, endo‐
myocardial biopsies; HTx, heart transplant recipients; ISHLT, International Society for Heart and Lung Transplanta‐
tion.
Two‐dimensional speckle‐tracking echocardiography (2D‐STE) was developed as an angle‐
independent echocardiographic modality to evaluate cardiac mechanical function. The 2D‐
STE‐derived parameters associated with rejection are also shown in Table 5 [28]. The
association between LV torsional deformation and rejection in transplant recipients has been
reported since the 1980s. Sato et al. reported that 2D‐STE‐derived LV torsion values are
decreased in patients with rejection, and the serial assessments of an intra‐patients comparison
showed that a cut‐off value of a 25% reduction of LV torsion from the baseline is associated
with ISHLT grade 2 or higher rejection, which returns to the baseline after adequate rejection
treatment (Figure 11) [34]. LV global strains are also calculated using 2D‐STE in an angle‐
independent manner. Sera F et al. reported that 2D‐STE‐derived LV global longitudinal strain
was associated with treatment‐requiring rejection [35] (Figure 12). In addition to its major
advantage of angle independency, 2D‐STE has other advantages over TDI, such as spatial
resolution, translational artifacts, the sensitivity to signal noise, the time needed for data
acquisition, and the necessity of employing expert readers. Three‐dimensional (3D) STEs are
useful echocardiographic modalities to assess various strain and rotation parameters more
accurately than 2D‐STE by tracking the same speckle throughout the cardiac cycle. However,
it will take several years for the validation studies of 3D‐STE to be performed to verify the
value of rejection‐detecting tools in heart transplant recipients.
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Figure 11. Representative 2D speckle‐tracking echocardiogram and analysis of torsion in a patient with and without
rejection. (quoted from Ref. [35]). Representative 2D‐STE imaging with rotation curves obtained from the same recipi‐
ent (a 32‐year‐old man) at LV short‐axis views of the apex (a, c) and the base (b, d). Each color of the deformational
curve represents one segment of the LV, and the dashed white curve depicts the mean rotation of six segments. The LV‐
tor, defined as the difference between apical basal end‐systolic rotation when the patient had ISHLT grade 2 rejection,
was 10.9 degrees (a, b). The LV torsion accompanied with ISHLT grade 0 after rejection treatment was 15.6 degrees (c,
d). The % change of LV torsion in this patient at the time of rejection was approximately 30% decreased from his base‐
line. ISHLT, International Society for Heart and Lung Transplantation; LV, left ventricular; 2D‐STE, 2D speckle‐tracking
echocardiography; EMB, endomyocardial biopsies; HTx, heart transplant recipients.
Figure 12. Representative 2D speckle tracking echocardiogram and analysis of global longitudinal strain in a patient
with and without rejection (quoted from Ref. [36]). LS curves obtained from a patient without rejection (grade 0) (A)
and another patient with grade 3a rejection (B). LS, longitudinal strain.
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3.2.3. Transplant vasculopathy and echocardiography
Echocardiography is a helpful and an ideal noninvasive tool to detect transplant vasculopathy
or chronic rejection as well. Dobutamine or/and exercise stress echocardiography has been
used to detect allograft vasculopathy, especially for pediatric patients or those with renal
insufficiency [36]. Decreases in strain and strain rates at rest and with dobutamine stress are
also useful to detect significant transplant vasculopathy. Contrast echocardiography is another
useful method.
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